Posts tagged: Ondine Biomedical

Ondine’s MRSAid Photodisinfection Technology Featured On National Canadian News

We couldn’t be any more excited by this! After announcing the results of our Vancouver General Hospital project, we were featured on national canadian news.  In this year-long quality improvement project, patients entering major select surgeries were treated with MRSAid Photodisinfection System and chlorhexidine body wipes. This was done to reduce their risk of developing surgical site infections. Here are highlights of the data:

  • Surgical site infections were reduced by 39%
  • Vancouver General Hospital saved ~$1.9 million
  • Readmissions due to surgical site infections decreased from 4 to 1.25 cases/month
  • 553 patient bed days were freed up
  • 138 more surgeries could be performed

We are grateful for the amazing work Dr. Elizabeth Bryce and her team at Vancouver General Hospital team has done to integrate MRSAid into their workflow. Check out these videos:

Read more »

Photodisinfection Kills MRSA Superbug Quickly and Safely

It is fair to say there are no microorganisms that cannot be killed by PDT (photodisinfection). It is a relatively non-specific formation of reactive oxidant species which, by and large, will kill anything. The way to optimize is to target the {‘photosensitizer’} to the species you want to kill – Richard Hamblin, Harvard Medical School.

One important application of photodisinfection is “nasal decolonization”, the elimination of all or almost all of the MRSA (Methicillin-resistant Staphylococcus aureus , one of the superbugs) that thrive inside of the nose. This is an important application because a number of studies have demonstrated that removing the harmful bacteria in the nose (called ‘decolonization’) results in a significantly lower incidence of surgical site infections. Patients who are colonized with bacteria are at risk of self contamination after surgeries when their bodies are weakened. By reducing all or substantially all of the harmful bugs in the nose prior to surgery, fewer patients will die and fewer patients will become infected with resistant and susceptible forms of staphylococcus (‘Staph’).

Read more »

From The Heart: A Personal Message From Ondine CEO Carolyn Cross

Creating new medical devices is not for the faint of heart.  One needs more than just a passion to prevent unnecessary deaths and improve the lives of mankind. One needs the conviction and the strength that come from a divine inspiration as well as the love and support of a large community of friends and family.  Without a doubt, championing a new technology in Canada is one of the hardest ventures that anyone can choose….and yet, I know that I am privileged to be tasked with this challenge.

Some of you know that I was recently in a terrible accident. When one looks at the circumstances surrounding my miraculous saving, it can only be the result of intervention of God and the Universe. I can count at least 17 miracles that occurred simultaneously to enable my survival on that fateful day. Surviving a plane crash is highly uncommon, we all know this. But having been up in the plane, having made my peace and having sent out my goodbyes, it was a true shock that I would be spared…and the only thought that went through my mind, at the time of that ordeal and every day since then, was that I was spared because I was needed in order to continue to champion photodisinfection. I believe with every fibre in my body that what we are doing at Ondine was important enough that my life needed to spared for this purpose.  This is the kind of conviction that is needed to take on the challenge of creating new life saving technologies and to overcome the constant barrage of negativity, doubt and disappointments.  Just as I was beginning to lose hope and stamina, I was given a big reminder of how fortunate I am to be able to carry on this mission.

Read more »

How Ondine Biomedical Addresses A World Of Growing Antibiotic Resistance

In 1969, the US Surgeon General William Stewart declared that the human race had won the war against bacteria. It was thought that bacteria would never be able to figure out how to develop resistance to the new complex antibiotics that had been created and that scientific researchers would always be able to stay well ahead of the bacteria. Today, it is well known that bacteria have reversed this situation and that the antibiotic resistance war is far from being over.

It is estimated that there are about 17 million people in the US alone annually suffering from painful and potentially harmful biofilm infections. To me and my colleagues at Ondine, we understand that certain bacteria have become dangerous and remain a threat to all of us. Every single one of us knows of a person who died, or nearly died, of an infection. Many of these people have died from infections acquired while in hospitals, a place where most of us think is safe. This just was not the case 20 years ago. This prevalence of deadly infections could not have been expected in 1969.  Our society’s overuse and misuse of antibiotics (over 25 million pounds of antibiotics are given to livestock every year) have led to greater threats to humanity. At the same time, the enormous costs and regulatory burdens have led to fewer new antibiotics being developed. Clearly the battle rages and we as humans have not been very strategic about our critical weapons. Read more »

Ondine Sponsored Pee Wee Hockey Team, The Unionville Jets, Win Gold For Canada!

Congratulations to The Unionville Jets Pee Wee hockey team on winning one for Canada! We couldn’t be more proud of you guys.

After coming off a win at the Shamrock tournament in Scarborough, the ’99 or Peewee Unionville Jets select team took their first bus trip to an out of town hockey tournament last weekend. Destination…the ‘Rock’n Roll’ Tournament in Cleveland Ohio.  It was an exciting weekend as bands like the Red Hot Chilli Peppers were being inducted into the Rock & Roll Hall of fame.

Ondine sponsored Unionville Jets Pee Wee hockey team celebrates their gold medal

Read more »

Ondine’s Photodisinfection Technology Being Developed To Treat Chronic Sinusitis

Photodisinfection is a highly effective antimicrobial therapy involving non-thermal light and a topically placed photosensitizer. It is currently being used for the treatment of oral infections and nasal decolonization of MRSA and S. aureus. Photodisinfection is also being currently used for the treatment of endotracheal tube biofilms to prevent ventilator associated pneumonia. One of the areas of medical need identified for photodisinfection is for the treatment of chronic sinusitis that has failed surgical and medical therapies. It is estimated that there are more than 500,000 of these people suffering in the US alone, and this number grows by 10% annually.

Polymicrobial biofilms, many of them antibiotic resistant, have been significantly implicated in the etiology of this chronic indolent disease process and its associated inflammatory processes.  Preclinical studies we have conducted demonstrate the effectiveness of photodisinfection to selectively photoeradicate a broad spectrum of biofilm micoorganisms, including antibiotic resistant S. aureus, P. aerugenosa and fungal species, without causing injury to tissue or mucosa.

Read more »

Ondine Study Shows Reduction of Endotracheal Tube Biofilm Using Photodisinfection

Ventilator-associated pneumonia is one of the most common and deadliest forms of healthcare-associated infections.  In the U.S alone, more than one million patients in healthcare facilities require mechanical ventilation every year. Up to 1 in 4 of these patients are reported to develop ventilator-associated pneumonia and up to half of them will die.1

Antimicrobial photodynamic therapy (aPDT), commonly known as Photodisinfection, is a non-invasive technique that used to study the reduction of biofilm in the lumen of an endotracheal tube. When patients undergo mechanical ventilation, an endotracheal tube is inserted into their throat to assist with breathing. This tube has long been recognized as a major factor in a patient’s risk for developing biofilm infections. For patients that require mechanical ventilation, such as those in ICUs, the biofilm can dislodge from the endotracheal tube and enter the lungs directly, often resulting in difficult-to-treat pneumonia.

Read more »

Working at Ondine: A Career Leading To A Harvard MBA

December 14, 2010 was a really special day for me. I was in my office when I got the news – I had been accepted to Harvard Business School’s MBA program. Now, as my time at Ondine comes to an end, I’ve been asked to recount my story, and how I got to the enviable position of being able to leave a job that I love for an unbelievable opportunity.

I began at Ondine in January of 2008 after returning from a backpacking trip around Western Europe. I had secured the internship the summer beforehand, and viewed it as the perfect opportunity. I had always been interested in business, but I was convinced that I would be attending dental school, having written the entrance examinations during my undergraduate degree. Ondine, having a commercially available dental product, was the hybrid I was looking for. So, armed with only my UBC degree in Cell Biology and Genetics, I set off to see what business was all about. Read more »

Ondine To Launch Ventilator-Associated Pneumonia (VAP) Photodisinfection Clinical Study

We are thrilled to announce that the FDA has approved a human clinical study to investigate the use of photodisinfection to prevent ventilator-associated pneumonia (VAP). VAP occurs when a lung infection develops in a patient ventilated with an endotracheal tube and continues to be the #1 cause of healthcare-associated infections in intensive care units. In the U.S alone, more than 1.3 million patients are mechanically ventilated every year. Of these patients, 10%-20% will develop ventilator-associated pneumonia, and up to half of them will die.

“A successful VAP study would represent a key step towards the commercialization of this new application of photodisinfection which utilizes Ondine’s patented technology and products…(our technology) has been proven to be highly effective at eliminating biofilms in ex vivo models, it is therefore ideally suited for the elimination of endotracheal tube biofilms resulting in the prevention of VAP” says Carolyn Cross, Chairman & CEO of Ondine.

Read more »

Ondine CEO, Carolyn Cross, Inducted Onto The Board of the International Photodynamic Association

“We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases…It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine.”

Carolyn Cross Inducted Onto Board of IPA

Our CEO has done it again. Two weeks after being featured in the Vancouver Sun Newspaper, Ms. Cross has now been inducted onto the Board of the International Photodynamic Association (IPA). Founded in 1986, the IPA brings together the most distinguished international clinicians and scientists involved in researching and developing photodynamic therapy. Ms. Cross will help raise awareness about the benefits of this technology and help bring it to the forefront of medicine.

We are very pleased to share this announcement with all of you today. Ms. Cross has been with Ondine for over a decade and was one of the initial founders and financial supporters of our company. Under her leadership, Ondine has developed a rapid R & D program and is now seen as one of the world’s most renowned group of experts on photodynamic therapy and photodisinfection. Read more »

Related Posts Plugin for WordPress, Blogger...

Staypressed theme by Themocracy